Welcome to HealthBanks

 

The HealthBanks network was created in response to the rapidly growing stem cell and gene therapy fields. Advancements being made in these fields are transforming the face of modern medicine, providing hope to families and helping give those battling terminal diseases a fighting chance.

 

What is HealthBanks?

HealthBanks is a company at the forefront of stem cell & immunotherapy research as well as the development of cell-based therapies to create better treatments for clinical diseases. We provide solutions for cell processing and cell storage and we’re hard at work developing new technology to aid in the cure of diseases once thought to be untreatable.

Our focus primarily lies in the areas of cord blood, cord tissue and immune cell banking.

 

Cord Blood and Cord Tissue

Cord blood and cord tissue are collected from the umbilical cord of a newborn where there is a rich source of hematopoietic stem cells. These special cells have been used in the treatment of over 80 diseases, including cancers, metabolic disorders, immune and blood related illnesses. Hematopoietic stem cells are similar to the ones traditionally found in an adult’s bone marrow. But, unlike bone marrow, the youth of the cells found in cord blood allows them to be able to replicate themselves for a much longer period of time.

When an individual has a disease that must be treated with chemotherapy or radiation, like Leukemia, there is a high probability that the treatments will negatively impact their immune system. The hematopoietic stem cells from the cord blood and tissue are used to replace the lost and damaged cells in the blood and immune system with new ones. These stem cells are able to adapt and replicate themselves allowing for more versatility in transplantation and disease treatment. With over 25,000 successful cord blood transplants performed worldwide, cord blood has helped patients live comfortably again.

The full capabilities of cord blood are still being thoroughly researched and tested. Clinical trials are currently underway to determine if it can be used as a regenerative therapy method for strokes, heart disease and even diabetes.

 

What is Cord Blood Banking

One of the major advantages of cord blood is that it can be frozen and stored indefinitely. You are able to store your child’s cord blood and tissue from the moment they are born and save it until the exact day that you need it. Similar to saving for retirement or buying health insurance, the benefits of proactively banking cord blood and tissue are long term and can help provide peace of mind.

 

Immune Cells and Immunotherapy

The immune system is the first line of defense against infection and diseases. When we are young, our immune system is usually enough to help us overcome most health issues. However, as we become older, these immune cells in our body begin to deteriorate and become less effective. With age, we are more susceptible to certain life threatening diseases, like  cancer, that can hijack our immune system and leave us defenseless.

 

Graph

 

The search to prolong our immune health has led to the development of immunotherapy, which leverages a patient’s immune cells to help treat their diseases. In the world of cancer immunotherapy, a promising new treatment known as CAR T-Cell therapy uses engineered T-cells from a patient’s own immune system to help them fight cancer.

The way CAR T-Cell therapy works is T-cells are collected from a patient’s blood, modified to produce special structures called chimeric antigen receptors (CARs) and then re-infused into the patient. These new CARs latch onto and kill specific antigens on the patient’s tumor cells, similar to how the body deals with other, more minor infections.

Currently, CAR T-cell therapy is FDA approved as a standard of care for aggressive, refractory non-Hodgkin lymphoma and for patients with relapsed or refractory acute lymphoblastic leukemia. CAR T-cell therapy has been shown to be highly effective in fighting these cancers,  with a full recovery of up to 92 percent in those who possessed Acute Lymphocytic Leukemia. FDA has approved 2 CAR T therapies in 2017. There are over 1,000 registered clinical trials currently going on world wide.

 

Why Choose Immune Cell Banking

Often, patients who need CAR T-Cell therapy already have compromised immune systems. Using their immune cells at that point is not nearly as effective as if they had preserved their cells when they were healthier. The best time to consider storing your immune cells is while they are still young and strong, before the onset of potential disease. In doing so, you are able to keep the best version of your own immune cells ready to help fight diseases like cancer in the future. Similar to storing cord blood and tissue, it is a long term investment in your future health.

 

How HealthBanks Can Help

Since HealthBanks’ inception in 2001, we have grown into one of the world’s leading private and public cell banking organizations. In 2019, we became the first cryobank network to offer immune cell banking and storage for future use in immunotherapies. With the emerging success of CAR T-cell therapies as a viable cancer treatment, we expanded our ever-evolving suite of cryopreservation solutions to meet growing demand. HealthBanks is proud to use the best automated technology and smart robotic storage solution to preserve your precious cells. No other private cell banks in the US uses the same caliber of technology to protect your investment.

Using the experience and knowledge of our executive team, HealthBanks is fulfilling its mission to make the benefits of cell and gene therapies accessible to everyone.

 

Bank Your Cells Today

Healthbanks offers comprehensive stem cell and immune cell banking options. Our state-of-the-art bioprocessing technology and world class customer service allows us to provide the best cord blood and immune cell banking experience in the industry. To learn more about our services and technologies and how you can begin investing in your future health today, visit our website healthbanks.us.

0Shares
0